CFRX ContraFect
WatchlistContraFect News
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersCVRx (NASDAQ:CVRX) stock moved upwards by 48.0% to $19.0 during Thursday's after-market session. The company's market cap stands at $394.3 million. As per the news, the Q3 earnings report came
ContraFect Corp Selling Securityholder May Offer And Sell Up To 7M Shares In Aggregate Of Common Stock
ContraFect Corp Selling Securityholder May Offer And Sell Up To 7M Shares In Aggregate Of Common Stock
ContraFect Has Received A Notice Of Allowance For Its U.S. Patent Application 16/629,916 Titled "Blood Component Potentiation Of Lytic Protein Anti-bacterial Activity And Methods And Uses Thereof"
ContraFect Has Received A Notice Of Allowance For Its U.S. Patent Application 16/629,916 Titled "Blood Component Potentiation Of Lytic Protein Anti-bacterial Activity And Methods And Uses Thereof"
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersBetter Therapeutics (NASDAQ:BTTX) stock rose 56.7% to $0.49 during Monday's pre-market session. The market value of their outstanding shares is at $19.9 million. Redhill Biopharma (NASDAQ:RDHL)
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study.
Ambrx Biopharma AMAM Phase 1⁄2 Data; ContraFect CFRX IND Cleared
12 Health Care Stocks Moving In Monday's Intraday Session
GainersAcurx Pharmaceuticals (NASDAQ:ACXP) stock increased by 57.3% to $3.02 during Monday's regular session. The current volume of 4.6 million shares is 2194.2% of Acurx Pharmaceuticals's average ful
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ParaZero Technologies Ltd. (NASDAQ:PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near p
12 Health Care Stocks Moving In Friday's After-Market Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) stock rose 15.4% to $0.3 during Friday's after-market session. Today's trading volume for this security ended up closing at 6.8 million shares, which is 1
Analysts' Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)
ContraFect Submits Investigational New Drug Application for Bacterial Pneumonia Treatment
ContraFect (CFRX) said Monday it has submitted an investigational new drug application that supports a proposed indication for CF-370 for the treatment of hospital-acquired bacterial pneumonia and ven
ContraFect Reports Submission Of IND Application To FDA For Its Development Candidate CF-370
The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacteri
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAxcella Health (NASDAQ:AXLA) stock rose 14.4% to $0.52 during Tuesday's after-market session. Axcella Health's trading volume hit 61.8 million shares by close, accounting for 4940.4% of its ave
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023 Download as PDF August 28, 2023YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a
ContraFect (CFRX) Receives a Buy From Maxim Group
Contrafect GAAP EPS of -$1.94 Misses by $0.13
Watching ContraFect; Zacks Small-Cap Research Sets $7 Price Valuation; Says This Model Is Highly Dependent Upon Clinical Success For Exebacase And Advancement Of Additional Lysin Products And Will Be Adjusted Accordingly Based Upon Future Clinical Results
Watching ContraFect; Zacks Small-Cap Research Sets $7 Price Valuation; Says This Model Is Highly Dependent Upon Clinical Success For Exebacase And Advancement Of Additional Lysin Products And Will Be
CVNA, BARK and MRKR Among Mid-day Movers
ContraFect Gains With Key Data Presentation Set for Next Week
Sientra, ContraFect Top Healthcare Gainers; Elevation, Longboard Among Losers